Jagsonpal Pharmaceuticals Limited has informed the Exchange about Transcript

Promoter Disclosed Acquisition PlansOrder Pipeline DisclosedAnalyst Day Multiyear TargetsInvestor Communications View source PDF

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-2.3%1-day move

₹215.00

prior close

₹212.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.9-1.4-1.1-1.2-2.3-0.3+1.1-2.8-1.4-4.0-3.7-6.0+10.7—

Up moveDown movePending

AI summary

Jagsonpal Pharmaceuticals reported Q4 FY26 revenue of INR64 crores (10% YoY growth) with PAT of INR9 crores (31% YoY). For full year FY26, revenue grew 7% to INR287 crores while profits from operations rose 19% to INR45 crores. The company outperformed the Indian Pharma Market, delivering 12.2% MAT growth versus industry growth of 7-8%, with Q4 growth accelerating to 14.2%. Management announced INR40 crores buyback at INR250/share and 200% dividend (including 75% special dividend), returning over INR66 crores to shareholders. The board targets 1.5x IPM growth (12-15%) going forward. Cash position exceeds INR190 crores with working capital cycle of just 11 days.

Likely market impact

Strong Q4 recovery driven by MR productivity improvements and brand focus; INR66 crores capital return signals management confidence in sustained cash generation and business acceleration.